Forest Ray

In the wake of last year's massive restructuring, Invitae is focused on developing its Personalized Cancer Monitoring product while integrating other oncology offerings.

Unique inflammation-associated gene expression signatures in adult and pediatric AML patients may speed risk stratification and treatment decisions.

The gene activity signature could serve as a predictive biomarker for HDAC6 inhibitor response among metastatic breast cancer patients.

In a validation study presented at SABCS, Myriad evaluated how well breast cancer risk assessments made with a clinco-genomic risk score aligned with observed incidence. 

Gaps in the biomarker testing process and knowledge deficiencies are keeping nearly two-thirds of lung cancer patients from receiving precision oncology treatments, research shows.

Researchers showed that methylation patterns on cell-free DNA in the eye can differentiate retinoblastomas into more or less aggressive subtypes.

Nonspecific language in California Gov. Gavin Newsom's veto of a bill to mandate insurance coverage of evidence-based biomarker tests caused confusion among the bill's proponents.

The funding is allocated to the California Initiative to Advance Precision Medicine for research related to depression and underrepresented populations.

The Tmod CAR-T platform uses tumor- and non-tumor-specific elements to spare normal cells while killing tumor cells without sacrificing cytotoxic potency.

A panel of 13 circulating proteins related to the tumor microenvironment may provide prognostic clues to prostate cancer progression.